In this issue of Rheumatology Nurse Practice, we review the latest PsA treatment guidelines and offer insight into how these recommendations can be translated into clinical practice. We also discuss data regarding the efficacy and safety of various classes of DMARDs, including conventional synthetic, biologic, and targeted small-molecule agents, and examine how providers can optimize their patients’ chances of treatment success with these options.
Linda Grinnell-Merrick, MS, NP-BC
University of Rochester Medical Center
Division of Allergy, Immunology, and Rheumatology
Carolyn Zic, MSN, FNP-BC
Comer Children’s Hospital
Laura P. Kimble, PhD, RN, FNP-C, CNE, FAHA, FAAN
This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.
After participating in the activity, learners should be better able to:
- Identify at least two physician and patient barriers preventing optimal care of psoriatic arthritis (PsA)
- Analyze key similarities and differences in published guidelines for the treatment of PsA
- Assess the appropriate utilization of biologic and small molecule therapies approved for the treatment of PsA
- Discuss the importance of setting realistic and attainable treatment goals for patients with PsA
Accreditation and Credit Designation
The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500)
Participants will receive 2.75 hours of continuing nursing contact hours, including 1.75 pharmacotherapeutic contact hours, by completing the education, completing an online evaluation, and receiving a post-test score of 70%.
According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE, Promotional event talks; H, Honoraria; O, Other.
Planners, reviewers, and faculty have disclosed no conflicts of interest related to the content of this education, with the exception of the following:
Linda Grinnell-Merrick, MS, NP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Janssen, Novartis, AbbVie/C, SB; Amgen, Sanofi/SB; Sandoz, UCB, Pfizer/C.
Carolyn Zic, MSN, FNP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Mallinckrodt/A.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be available to you upon completion.
© 2021. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
This course will expire on March 30, 2022